Lamotrigine-associated rash: Risk/benefit considerations in adults and children

Epilepsia

Volumn 40, Issue 7, 1999, Pages 985-991

  Guberman, Alan H ^a,b   Besag, Frank M C ^a   Brodie, Martin J ^c   Dooley, Joseph M ^d   Duchowny, Michael S ^e   Pellock, John M ^f   Richens, Alan ^g   Stern, Robert S ^h   Trevathan, Edwin ⁱ  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Centre for Epilepsy   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d IWK HEALTH CENTRE   (Canada)

^e MIAMI CHILDREN'S HOSPITAL   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antiepileptic drug rash; Epilepsy; Lamotrigine; Stevens Johnson syndrome

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ADULT; ARTICLE; CHILD; CLINICAL PRACTICE; DRUG EFFECT; DRUG HYPERSENSITIVITY; EPILEPSY; HOSPITALIZATION; HUMAN; MEDICAL SPECIALIST; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; STEVENS JOHNSON SYNDROME;

EID: 0342301745     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00807.x     Document Type: Article

References (44)

1. Glaxo-Wellcome, Lamictal Advisory Board Briefing Document, October 23, 1997.
2. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713.
3. Binnie CD. Van Emde Boas W, Kastelijn-Nolste-Trnite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
4. Eriksson A-S, Hoppu K, NergDrdh A, Boreus L. Pharmacokinetics of lamotrigine in children with intractable epilepsy [Abstract]. J Epilepsy 1994;7:326.
5. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
6. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
7. Chapman AA, Keane PE, Meldrum BS, Simiand J, Vernieres JC. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:315-59.
8. Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-3.
9. Besag FMC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-7.
10. Binnie CD. The efficacy of lamotrigine. Rev Contemp Pharmacother 1994;5:115-22.
11. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in partial seizures: U.S. Lamotrigine Protocol 05 Clinical Trial Group. Neurology 1993;43: 2284-91.
12. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-21.
13. Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997;337:1807-12.
14. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
15. Brodie MJ, Richens A, Yuen AWC, for the Lamotrigine/ Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
16. Perucca E. Add-on trial of lamotrigine followed by withdrawal of concomitant medication and stabilization on monotherapy. In: Loiseau P, ed. Lamotrigine: a brighter future. International Congress and Symposium Series 214. London: Royal Society of Medicine Press, 1996:23-30.
17. Steiner TJ, Siveira C, Yuen AWC, and the North Thames Lamictal Study Group. Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy [Abstract]. Epilepsia 1994;35(suppl 7):61.
18. Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res 1997;26:423-32.
19. Chang G. Lamictal (lamotrigine) monotherapy is a safe and effective treatment for partial seizures. Epilepsia 1997;38(supp] 3):S32.
20. Schachter S, Leppik I, Matsuo F, et al. for the US Lamotrigine Protocol 16 Clinical Study Group. A multicenter, placebo-controlled evaluation of the safety of lamotrigine (Lamictal) as add-on therapy in outpatients with partial seizures [Abstract]. Epilepsia 1992;33(suppl3):119.
21. Foletti G, Schmidt M, Delisle MC, Molleyres D, Volanschi D. An open study on effectiveness of lamotrigine in the treatment of secondary bilateral synchrony, unsatisfactorily controlled by conventional drugs [Abstract]. J Neurol 1992;239(suppl 2):S71.
22. Oller LFV, Russi A, Oller Daurella L. Lamotrigine in the Lennox-Gastaut syndrome [Abstract], Epilepsia 1991;32(suppl 1):58.
23. Uvebrant P, Bauzien PR. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-9.
24. Richens A. Safety of lamotrigine. Epilepsia 1994;35(suppl 5):S37-40.
25. Besag FMC, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal7) in paediatric patients with epilepsy. Seizure 1997;6:51-6.
26. Dooley J, Camfield P, Gordon K, Camfield C, Wirrell E, Smith E. Lamotrigine-induced rash in children. Neurology 1996;46:240-2.
27. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
28. Besag FMC. Reintroduction of lamotrigine after rash with initial exposure. Epilepsia 1997;38(suppl 8):S102.
29. Tavernor SJ, Wong ICK, Newton R, Brown SW. Rechallenge with lamotrigine after initial rash. Seizure 1995;4:67-71.
30. Manasco P, Mullens L, Matsuo F. Skin rash associated with Lamictal: incidence, time to onset and risk factors. Epilepsia 1996;37 (suppl 5):S164.
31. Brodie M. Lamotrigine monotherapy: an overview. In: Loiseau P, ed. Lamotrigine a brighter future. International Congress and Symposium Series 214. London: Royal Society of Medicine Press, 1996:43-9.
32. Wolkenstein P, Revuz J. Drug-induced severe skin reactions: incidence, management and prevention. Drug Safety 1995;13:56-68.
33. Chaffin JJ, Davis SM. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacother 1997;31:720-3.
34. Fogh K, Mai J. Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). Seizure 1997;6:63-5.
35. Sachs B, Ronnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine-induced SJS: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997; 195:60-4.
36. Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995;33:595-7.
37. Sullivan JR, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol 1996;37:208-12.
38. Wadelius M, Karlsson T, Wadelius C, Rane A. Lamotrigine and toxic epidermal necrolysis. Lancet 1996;348:1041.
39. Mackay FJ, Wilton LV, Pearce SN, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997;38:881-6.
40. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
41. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a recorded linkage study. Neurology 1997;49:542-6.
42. Konishi T, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993;152:605-8.
43. King JA, Knight JE. Low incidence of rash associated with slow titration of lamotrigine. Epilepsia 1997;38(suppl 3):S32.
44. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998; 18:281-96.